COVID-19 has changed our lives, very suddenly and in dramatic ways that we never imagined. One thing that hasn't changed is Agilent's commitment to providing answers to the critical questions and challenges you face in this very difficult global situation.
We are here with you, driven by common objectives: staying safe, keeping essential labs around the world running, and collaborating in the fight against COVID-19.
We are grateful that you look to Agilent during this time to provide solutions and insights that help your labs operate effectively — even with reduced and remote staff — and help you rapidly advance the discoveries the world needs. The information here is designed to keep you informed of our efforts, support you in your efforts, and inspire you to keep moving forward.
At Agilent, supporting our customers and employees is a key priority, and our global teams are hard at work to avoid disruptions from the COVID-19 virus while at the same time acting responsibly to do what we can to prevent further spread.
Vaccine and therapies are all needed as fast as possible. Understanding the novel coronavirus is key, as is working together on these two critical components.
COVID-19 has forced us all to look for ways to maintain productivity with less time in the lab or on site. While it can be challenging, it can also be a good time to refresh and acquire new skills, and learn from others. Agilent is here to support you and is offering many online resources that you can take advantage of.
Homemade hand sanitizer, 3D-printed face shields and volunteerism. In a time of uncertainty, our people chose to take initiative and respond to the call by thinking outside of the box and extend their hearts to others.
We want you to feel confident in Agilent and in our commitments for delivery, service and support, so we have compiled answers to common questions and have provided a path for you to contact us for additional COVID-19 questions.
Read and watch media coverage of how Agilent is helping our customers with solutions to combat COVID-19. On CNBC, Agilent CEO Mike McMullen talks with Jim Cramer of "Mad Money" about accelerating the flow of coronavirus testing. Other news outlets outline how Agilent is at the forefront of research for a vaccine.